Celularity Celularity
  • Home
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Manufacturing
    • Biobanking
    • Tour Our Facility
    • Expanded Access Policy
  • Science
    • Power of Placenta
    • NK Cell Platform
    • T Cell Platform
    • Exosomes
    • Advanced Biomaterials
  • Pipeline
  • Newsroom
  • Investors
    • Investor Relations
    • SEC Filings
    • Corporate Governance
  • Careers
Celularity
MENU

T Cell Platform

Placental-derived Chimeric Antigen Receptor T cells
Pipeline

P CAR-T cells are in development for the treatment of hematological and solid tumor indications. We have demonstrated that pCAR-T cells exhibit potent anti-tumor activity both in vitro and in vivo.

– Xiaokui Zhang, PhD, Chief Scientific Officer

CyCART

Cryopreserved Chimeric Antigen Receptor T cells

Allogeneic P CAR-T with TCR KO

Placental derived T Cell with CAR expression

Chimeric Antigen Receptor T cells (CAR-T) are genetically engineered T cells that are modified to express an artificial T cell receptor on their surface that binds and targets cancer proteins in an HLA-independent manner.

We are developing an allogeneic placental T cell platform derived from the postpartum human placenta. Placental T cells are engineered with CAR expression, and knockout of endogenous T cell receptors (TCR) termed P CAR-T.

Unlike adult peripheral blood mononuclear cell derived T cells, placental-derived CAR T cells are mostly naïve (CD45RA+), expand readily ex vivo, express markers of stem cell memory, and have lower expression of effector or exhaustion markers, allowing for greater proliferative potential of these cells in vivo.

P CAR-T cells are in development for the treatment of hematological and solid tumor indications. We have demonstrated that pCAR-T cells exhibit potent anti-tumor activity both in vitro and in vivo.

Several CAR-T cell therapies have already been approved by the FDA, but these treatments all require extraction and processing of a patient’s own cells, an expensive and non-scalable process. Celularity is developing placental-derived CAR-T cells as an allogeneic cell therapy that can be used without the need to match patient with donor.

– Robert J Hariri, MD, PhD

RESOURCES

61ST ASH ANNUAL MEETING, 2019, POSTER SESSION
Preclinical Evaluation of Human Placental-derived Allogeneic CD19 CAR-T Cells Against B Cell Malignancies

AACR ANNUAL MEETING 2020, POSTER SESSION
Generation and Characterization of Human Placental-derived CD19 CAR-T Cells Using Viral Vectors

Celularity_Nasdaq_CELU-1

Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases.

Company

  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers

Science

  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing

Investors

  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2025. All rights reserved.     Privacy Policy     Terms & Conditions

Company
  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers
Science
  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing
Investors
  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2024. All rights reserved.
Privacy Policy     Terms & Conditions